CD95-Fc fusion proteins
View Patent ↗The invention relates to fusion proteins comprising at least a first domain and a second domain selected from a constant Fc immunoglobulin domain.
1. A fusion protein comprising
(i) at least one first domain comprising a ligand binding domain of the CD95 receptor fused to
(ii) a heterologous second domain comprising at least a portion of a constant immunoglobulin domain, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO: 18.
2. The fusion protein of claim 1 , wherein the second domain is an Fc fragment of a constant heavy immunoglobulin domain comprising the CH2 and CH3 domain.
3. The fusion protein of claim 1 , further comprising an N-terminal signal sequence.
4. A pharmaceutical composition comprising as an active agent the fusion protein of claim 1 .
5. A fusion protein comprising the amino acid sequence of SEQ ID NO: 15.
6. An isolated nucleic acid molecule encoding the fusion protein of claim 1 .
7. The nucleic acid molecule of claim 6 which is operatively linked to an expression control sequence.
8. A vector comprising the nucleic acid molecule of claim 6 .
9. An isolated cell transformed or transfected with the nucleic acid molecule of claim 6 .
10. The cell of claim 9 which is a prokaryotic cell.
11. The cell of claim 9 which is a eukaryotic cell.
12. The cell of claim 9 which is a mammalian cell.
13. The cell of claim 9 which is a human cell.
14. A composition comprising the nucleic acid molecule of claim 6 and a pharmaceutically acceptable carrier.